Scarica l'app Stockscreener
2.76
1.47%
0.04
Dopo l'orario di chiusura:
2.79
0.03
+1.09%
Perspective Therapeutics Inc Borsa (CATX) Ultime notizie
Form 8K Perspective Therapeutics Inc For: 1 October By Investing.com - Investing.com India
Three cancer programs are in trials. Perspective Therapeutics (CATX) reports early melanoma results. - Stock Titan
Form 13D/A Perspective Therapeutics For: 26 September By Investing.com - Investing.com Nigeria
Perspective Therapeutics Inc (CATX) Stock Price Target & Forecast - TradingKey
After selling nearly 1.4 million shares in one day, a Perspective Therapeutics (CATX) holder still has a stake. - Stock Titan
Perspective Therapeutics Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesEPS Consistency Score - siam.in
Perspective Therapeutics (CATX) Climbs 3.13% to $2.97, Nearing Resistance at $3.12Mutual Fund Flow - dars.gov.et
Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
This $3 Biotech Could Be Worth $11.45, Analyst Says - benzinga.com
William Blair initiates Perspective Therapeutics stock with outperform rating - Investing.com
William Blair Initiates Perspective Therapeutics With Outperform Rating - marketscreener.com
William Blair initiates Perspective Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
William Blair Initiates Perspective Therapeutics(CATX.US) With Buy Rating - Moomoo
Perspective Therapeutics Inc (CATX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BMO Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Perspective Therapeutics partners with Merck on cancer trial By Investing.com - Investing.com South Africa
Perspective Therapeutics partners with Merck on cancer trial - Investing.com
Form 8K Perspective Therapeutics Inc For: 14 September By Investing.com - Investing.com UK
Merck joins Perspective Therapeutics (NYSE: CATX) to test Keytruda combo in Phase 1/2a cancer trial - Stock Titan
Perspective Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate PSV359 in Combination with Keytruda in Advanced FAP-α-Positive Solid Tumors - quiverquant.com
Perspective Therapeutics to present NET therapy trial data - grafa.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 - Yahoo Finance
Perspective Therapeutics (CATX) Insider Sale: 10% Owner Lantheus Alpha Therapy, LLC Sells 247,932 Shares - GuruFocus
Perspective Therapeutics updates corporate presentation highlighting 212Pb pipeline, $45B addressable market - TradingView
Perspective Therapeutics (CATX) highlights 3 cancer drug programs - Stock Titan
Perspective Therapeutics (CATX) holder sells stock near $3.10 - Stock Titan
Lantheus Alpha Therapy Sells 113,914 Perspective Therapeutics (AMEX: CATX) Shares at Up to $3.14 Per Share - Kalkine Media
Lantheus Group Reduces Stake in Perspective Therapeutics (AMEX: CATX) to 10% Amid Activist 13D Filing - Kalkine Media
Lantheus Holdings (NASDAQ: LNTH) 10% Stakeholder Alpha Therapy Sells 42,129 Shares at $3.11 Each - Kalkine Media
Perspective Therapeutics (CATX) Insider Sell: 10% Owner Lantheus Alpha Therapy, LLC Disposes of 42,129 Shares - GuruFocus
Lantheus Holdings (NASDAQ: LNTH) Disposes of 35,769 Perspective Therapeutics Shares at $3.12 Each - Kalkine Media
Perspective Therapeutics (CATX) backer trims stake but keeps 11.5M shares - Stock Titan
10% owner of Perspective Therapeutics (NYSE: CATX) sells 113,914 shares over two days - Stock Titan
Perspective Therapeutics (CATX) backer Lantheus now owns 10% after share sales - Stock Titan
Perspective Therapeutics Inc (CATX) Insider Sell: 10% Owner Holdings, Lantheus Disposes of 35,769 Shares - GuruFocus
Perspective Therapeutics (CATX) holder sells 35K shares, still owns 11.6M - Stock Titan
Perspective Therapeutics Inc (CATX) Insider Sell: 10% Owner Holdings, Lantheus Disposes of 78,145 Shares - GuruFocus
Lantheus Holdings sells $245,609 in Perspective Therapeutics stock By Investing.com - Investing.com Nigeria
Lantheus Holdings sells $245,609 in Perspective Therapeutics stock - Investing.com
Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans - Seeking Alpha
Perspective Therapeutics (CATX) Slides 3.19% as $3.03 Support Comes into FocusMomentum Surge Alerts - vinanet.vn
Perspective (CATX) Quarterly Results: Reported EPS Tops Expectations at the Close; Post-Earnings: The Market Price Declines 3.03% for the Current SessionProfit Inflection Point - vinanet.vn
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Eastern Progress
BMO Capital Markets Upgrades Perspective Therapeutics (NYSEAMERICAN:CATX) to "Strong-Buy" - MarketBeat
Perspective (CATX) Range: Posts a 8.41% Gain to $3.48 for the Current Session; Chart View - vinanet.vn
PERSPECTIVE THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $11 - Bitget
Perspective Therapeutics Market Sentiment - Benzinga France
CATX Initiated by BMO Capital -- Rating Set to Outperform - GuruFocus
Perspective Therapeutics Price Target Announced at $11.00/Share by BMO Capital - Moomoo
BMO initiates Perspective Therapeutics stock at Outperform, $11 target By Investing.com - Investing.com South Africa
BMO initiates Perspective Therapeutics stock at Outperform, $11 target - Investing.com
BMO Capital Initiates Perspective Therapeutics at Outperform - marketscreener.com
BMO Capital Initiates Coverage on CATX with Outperform Rating, H - GuruFocus
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
CATX Q1 2026 Earnings: Narrower-Than-Expected Loss Supports 3.23% Stock AdvanceRevenue Warning Signal - careplusvn.com
0.26%
0.38%
Capitalizzazione:
|
Volume (24 ore):